Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug therapy in chronic heart failure.

D B McKenzie1, A J Cowley

  • 1Department of Cardiovascular Medicine, University Hospital, Nottingham, UK. dan.mckenzie@nottingham.ac.uk

Postgraduate Medical Journal
|December 5, 2003
PubMed
Summary

Chronic heart failure (CHF) management has evolved beyond diuretics and digoxin. Angiotensin converting enzyme inhibitors and beta-blockers improve survival, with other agents showing promise for this widespread condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Four-valve endocarditis caused by group G Streptoccocci.

BMJ case reports·2025
Same author

Four-valve endocarditis caused by group G Streptoccocci.

BMJ case reports·2011
Same author

Lymphoma presenting as an ejection systolic murmur.

European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology·2007
Same author

Four-valve endocarditis caused by group G Streptoccocci.

Heart (British Cardiac Society)·2007
Same author

Beneficial haemodynamic effects of insulin in chronic heart failure.

Heart (British Cardiac Society)·2001
Same author

Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2000

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) is a prevalent and progressive condition leading to significant disability and reduced lifespan.
  • Traditional treatments include diuretics and digoxin, which have been used for decades.

Observation:

  • Clinical trials have established the efficacy of angiotensin converting enzyme (ACE) inhibitors and beta-blockers in improving symptoms and reducing mortality in selected CHF patients.
  • Angiotensin-II receptor blockers (ARBs) and spironolactone are also recognized for their potential benefits in specific patient groups.

Findings:

  • Established therapies like ACE inhibitors and beta-blockers are crucial for managing chronic heart failure.
  • Emerging pharmacological agents are under investigation for enhanced CHF treatment strategies.

Implications:

  • Current treatment guidelines incorporate ACE inhibitors and beta-blockers for improved patient outcomes in chronic heart failure.
  • Ongoing research into novel pharmacotherapies may offer new avenues for managing this complex cardiovascular disease.

Related Experiment Videos